PlantPharm BioMed


Developer of a plant-based platform for production and oral delivery of vaccines and biopharmaceuticals. The platform uses genetically stable, clonal propagation in plants to express vaccine antigens and other therapeutic proteins, enabling shelf-stable oral solid dose formulations (tablets, capsules) for humans and pelletized feed for animals. The organization has supported this approach with >30 years of R&D, field testing and a double-blind human clinical trial of an oral Hepatitis B vaccine, and is engaged in government-collaborative projects for animal vaccine development.

Industries

biotechnology

Nr. of Employees

small (1-50)

PlantPharm BioMed


Products

Oral solid dose Hepatitis B vaccine (clinical lot)

A plant-produced oral solid dose formulation of Hepatitis B vaccine evaluated in a double-blind human clinical trial and reported to be equivalent to standard comparators.


Services

Collaborative service to convert existing injectable vaccines and biopharmaceuticals into plant-produced oral solid dose or pelletized feed formats for expanded market access.

Development and production of pelletized feed vaccines and bait-station delivery systems for wildlife and farmed animals.

Execution of government-funded research projects for development of animal vaccine products and participation in One Health initiatives.

Expertise Areas

  • Plant-based vaccine production
  • Oral solid dose vaccine formulation
  • Animal vaccine delivery via feed
  • Mucosal immunization strategies
  • Show More (4)

Key Technologies

  • Plant molecular expression systems
  • Clonal plant propagation
  • Oral solid dose (OSD) formulation
  • Pelletized feed vaccine delivery
  • Show More (3)

News & Updates

Presentation at World Vaccine Congress (April 22-24, 2025) discussing development of a pelletized feed vaccine for COVID-19 in animals.

Announcement of presentation on plant-based SARS-CoV-2 vaccine research at an international One Health symposium.

Press article (BizTimes) summarizing the company's efforts to develop plant-based edible vaccines (external media coverage referenced on site).

Award of more than $900,000 from the U.S. Department of Agriculture Animal and Plant Health Inspection Service to develop a feed-delivered SARS-CoV-2 vaccine for animals.

Growth of a plant crop containing Hepatitis B vaccine antigen and completion of an FDA-authorized double-blind human clinical trial demonstrating equivalence to standard Hepatitis B vaccines.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.